Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eur J Haematol ; 56(5): 308-12, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8641405

RESUMEN

Thirteen consecutive adult patients with primary refractory (n = 5) or relapsed (n = 8) acute lymphoblastic leukemia (ALL) were treated by an induction schedule (FLAG) consisting of Fludarabine (30 mg/sqm/d) plus high dose Cytarabine (HD-ara-C: 2 g/sqm/d) (d 1-5) and G-CSF (from d O to polymorphonuclear recovery). Patients achieving complete remission (CR) were administered a second FLAG course as consolidation and were then submitted to an individualized program of post-remission therapy, depending on the patient's age and performance status. CR was achieved in 8/12 evaluable cases (67%). The median CR duration was 22.5 w. CR attainment was significantly related to the co-expression of lymphoid and myeloid antigens. ALL/My+ patients achieved CR in 6/6 evaluable cases vs. 2/6 for ALL/My+. In vitro 3H ara-C incorporation into cellular DNA resulted significantly increased by Fludarabine (in 7/9 tested cases) and, furthermore, by the association of Fludarabine G-CSF in 5 evaluable ALL/My+ cases; in contrast, no effect of G-CSF addition to Fludarabine was observed in 4 ALL/My. Myelosuppression was observed in all patients: the median time to neutrophils > 0.5 x 10(9)/1 was 16.3 d (range 13-22) and 16.2 d (range 9-29) to platelets > 20 x 10(9)/1. Nonhematological toxicity was minimal. In conclusion, FLAG is an active and tolerable combination in refractory ALL, particularly in cases with myeloid antigen expression where G-CSF appears to improve efficacy, probably increasing ara-C incorporation into the DNA of leukemic cells.


Asunto(s)
Antígenos de Neoplasias/biosíntesis , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Adulto , Antígenos de Neoplasias/análisis , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Conjuntivitis/inducido químicamente , Conjuntivitis/prevención & control , Citarabina/administración & dosificación , Citarabina/efectos adversos , Supervivencia sin Enfermedad , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/uso terapéutico , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Soluciones Oftálmicas , Inducción de Remisión , Vidarabina/administración & dosificación , Vidarabina/análogos & derivados
2.
Minerva Chir ; 35(3): 101-4, 1980 Feb 15.
Artículo en Italiano | MEDLINE | ID: mdl-7374966

RESUMEN

The biofeed-back technique is based on the concept of the voluntary control of visceral functions and derives from the clinical application of the theory of operative conditioning. After a brief mention of general concepts and the various application fields of biofeed-back, a personal proposal for the use of this technique in the treatment of oesophageal dysfunctions of psychosomatic origin with the aid of oesophageal manometry is put foward.


Asunto(s)
Biorretroalimentación Psicológica , Enfermedades del Esófago/terapia , Manometría , Trastornos Psicofisiológicos/terapia , Animales , Enfermedades del Esófago/diagnóstico , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA